Recursion is more than a coding trick—it’s a powerful way to simplify complex problems in Python. From elegant tree traversals to backtracking algorithms, mastering recursion opens the door to cleaner ...

It’s July 20, 1969. Neil Armstrong and Buzz Aldrin are about to land on the moon. They will be the first humans to set foot ...

Hundreds of packages across npm and PyPI have been compromised in a new Shai-Hulud supply-chain campaign delivering ...

If you’re an AP Computer Science student using CodeHS, you’re about to get a significant upgrade: the platform is refreshing its Python curriculum for Fall 2026 with improved autograders, clearer ...

While previous assessments categorized AI-assisted cyberattacks as experimental, current data suggests generative AI is now a mature, industrialized component of offensive operations.

Attackers compromised the official Mistral AI Python package on PyPI along with hundreds of other widely-used developer packages, exposing GitHub tokens, cloud credentials, and password vaults across ...

Arcjet thinks it has the answer. The company this week introduced Guards, a service designed to enforce security inside AI ...

According to Rogers, the computer science faculty use Gradescope’s Measure Of Software Similarity (MOSS) tool to identify ...

Meta's new hyperagent framework breaks the AI "maintenance wall," allowing systems to autonomously rewrite their own logic and scale across tasks without constant human engineering.

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...